Sarah Cannon Research Institute
@scri.com
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.
Pinned
Sarah Cannon Research Institute
@scri.com
· Mar 25
SCRI is transforming cancer care through groundbreaking trials at 250 locations in 24 states. Join us in advancing therapies and offering hope.
Watch how we collaborate to make a difference.
#CancerResearch #ClinicalTrials #NewHope #SCRI
scri.com
Watch how we collaborate to make a difference.
#CancerResearch #ClinicalTrials #NewHope #SCRI
scri.com
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
November 7, 2025 at 5:59 PM
November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...
New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer | CancerNetwork
The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.
www.cancernetwork.com
October 30, 2025 at 7:25 PM
New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05
Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story
Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story
www.thedrewbarrymoreshow.com
October 28, 2025 at 7:51 PM
Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts
SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Stage 1 Testicular Cancer: A Patient Education Overview | CURE
From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.
www.curetoday.com
October 28, 2025 at 5:07 PM
SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI
PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years | AJMC
A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.
www.ajmc.com
October 23, 2025 at 5:51 PM
PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy
The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways | AJMC
Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.
www.ajmc.com
October 22, 2025 at 6:12 PM
The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
October 9, 2025 at 7:35 PM
Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
October 6, 2025 at 6:08 PM
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
His legacy: 850+ first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update:
www.scri.com/news/scri-an...
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
October 2, 2025 at 5:14 PM
At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
September 29, 2025 at 2:32 PM
Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer
🎧 SCRI’s Dr. Garmezy & Dr. Bupathi share expert insights on treating variant histologies in GU cancers at #WorldGU2025 on Oncology Decoded.
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded
Episode 12: Variant Histology Treatment Considerations From World GU 2025 | CancerNetwork
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
www.cancernetwork.com
September 26, 2025 at 6:58 PM
🎧 SCRI’s Dr. Garmezy & Dr. Bupathi share expert insights on treating variant histologies in GU cancers at #WorldGU2025 on Oncology Decoded.
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded
Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
September 25, 2025 at 10:13 PM
Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories
Dr. Hans Lee & Dr. Kris Patel from SCRI Oncology share how new therapies like CAR T-cell treatment are changing lives.
📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
How Blood Cancer Research Is Advancing Treatment | Dr. Hans Lee & Dr. Kris Patel on News Channel 5
YouTube video by Sarah Cannon Research Institute
www.youtube.com
September 19, 2025 at 8:17 PM
Dr. Hans Lee & Dr. Kris Patel from SCRI Oncology share how new therapies like CAR T-cell treatment are changing lives.
📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
Dr. Jason Henry featured on @DenverChannel discussing early data from a promising #pancreaticcancer vaccine.
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...
Early data for new pancreatic cancer vaccine generating hope among patients, researchers
Early data for a new vaccine for pancreatic cancer is generating some hope among patients and researchers.
www.denver7.com
September 12, 2025 at 8:23 PM
Dr. Jason Henry featured on @DenverChannel discussing early data from a promising #pancreaticcancer vaccine.
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...
“Prostate cancer is often treatable—if caught early.”
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology
What You Need to Know About Prostate Cancer Awareness | Dr. Benjamin Garmezy on News Channel 5
YouTube video by Sarah Cannon Research Institute
youtu.be
September 5, 2025 at 4:13 PM
“Prostate cancer is often treatable—if caught early.”
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology
Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope
#AML #SCRI #ClinicalTrials #Hope
September 2, 2025 at 1:00 PM
Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope
#AML #SCRI #ClinicalTrials #Hope
New studies in ASH’s Blood Advances show significant quality-of-life gains for patients with #SickleCell & #BetaThalassemia.
From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.
#GeneTherapy #ExaCel #CRISPR #Hematology
From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.
#GeneTherapy #ExaCel #CRISPR #Hematology
Gene therapy is changing lives! For patients with sickle cell disease and beta thalassemia, exa-cel means freedom from hospital visits and a renewed quality of life. 🔗 Learn more in the press release: https://bit.ly/3HTDvM8
@hfrangoul.bsky.social
@hfrangoul.bsky.social
August 27, 2025 at 5:21 PM
New studies in ASH’s Blood Advances show significant quality-of-life gains for patients with #SickleCell & #BetaThalassemia.
From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.
#GeneTherapy #ExaCel #CRISPR #Hematology
From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.
#GeneTherapy #ExaCel #CRISPR #Hematology
Dr. Hans Lee joins OncLive On Air to discuss FDA approval of linvoseltamab for relapsed/refractory multiple myeloma. A new option for patients with limited therapies.
🔗 www.onclive.com/view/fda-app...
#MultipleMyeloma #SCRI #FDAApproval
🔗 www.onclive.com/view/fda-app...
#MultipleMyeloma #SCRI #FDAApproval
FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD
Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.
www.onclive.com
August 26, 2025 at 12:00 PM
Dr. Hans Lee joins OncLive On Air to discuss FDA approval of linvoseltamab for relapsed/refractory multiple myeloma. A new option for patients with limited therapies.
🔗 www.onclive.com/view/fda-app...
#MultipleMyeloma #SCRI #FDAApproval
🔗 www.onclive.com/view/fda-app...
#MultipleMyeloma #SCRI #FDAApproval
Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
August 25, 2025 at 1:00 PM
Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories
Early data from a personalized mRNA vaccine shows promise in delaying recurrence in pancreatic cancer. Dr. Jason Henry shares why this is generating hope.
🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI
🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI
Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence
Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.
www.onclive.com
August 22, 2025 at 1:00 PM
Early data from a personalized mRNA vaccine shows promise in delaying recurrence in pancreatic cancer. Dr. Jason Henry shares why this is generating hope.
🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI
🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI
FDA accepts NDA for vepdegestrant in ER+/HER2– metastatic breast cancer. Dr. Erika Hamilton highlights the VERITAC-2 trial’s impact on this promising therapy.
🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval
🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval
FDA Accepts NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Breast Cancer
The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.
www.onclive.com
August 21, 2025 at 1:00 PM
FDA accepts NDA for vepdegestrant in ER+/HER2– metastatic breast cancer. Dr. Erika Hamilton highlights the VERITAC-2 trial’s impact on this promising therapy.
🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval
🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval
In Oncology Decoded, SCRI's Drs. Bupathi and Garmezy, discuss evolving strategies for treating urothelial carcinoma beyond first-line therapy, particularly in light of recent FDA approvals.
Listen to the episode: www.cancernetwork.com/view/episode...
Listen to the episode: www.cancernetwork.com/view/episode...
August 20, 2025 at 1:29 PM
In Oncology Decoded, SCRI's Drs. Bupathi and Garmezy, discuss evolving strategies for treating urothelial carcinoma beyond first-line therapy, particularly in light of recent FDA approvals.
Listen to the episode: www.cancernetwork.com/view/episode...
Listen to the episode: www.cancernetwork.com/view/episode...
Lisa’s story is one of resilience and research.
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
August 19, 2025 at 3:25 PM
Lisa’s story is one of resilience and research.
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...
#PatientStories
Welcome Dr. Sarah Premji to Sarah Cannon Research Institute! As Assistant Director of Breast Cancer Research, she brings deep expertise and passion for patient-centered care.
📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer
📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer
August 18, 2025 at 1:08 PM
Welcome Dr. Sarah Premji to Sarah Cannon Research Institute! As Assistant Director of Breast Cancer Research, she brings deep expertise and passion for patient-centered care.
📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer
📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer
🧬 “AQUILA is a big trial… and there’s a trend toward improved OS.”
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.
ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.
ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...
Dr Burke Discusses Daratumumab in Smoldering Myeloma
John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.
www.targetedonc.com
August 15, 2025 at 1:00 PM
🧬 “AQUILA is a big trial… and there’s a trend toward improved OS.”
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.
ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.
ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...